Semaglutide & Tirzepatide

Fat LossApproved incretin class overviewEstablished

Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Not a single combination drug.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): —
Half-life: See individual products (~5–7 days)
Unit: mg
Administration Route: Subcutaneous
Frequency: 1× weekly
Last updated: 8/23/2026
Targets: GLP-1 receptorGIP receptor (tirzepatide)

Overview

Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Not a single combination drug.

Protocol

Dosage Range: Semaglutide: 0.25→2.4 mg weekly; Tirzepatide: 2.5→10–15 mg weekly (titrate)
Frequency: 1× weekly
Cycle: Long-term use for obesity/diabetes; reassess periodically
Administration Route: Subcutaneous
Reconstitution Guide: —

Science

Mechanism of Action

Semaglutide is a GLP-1RA; tirzepatide is a dual GIP/GLP-1 RA. Both reduce appetite and improve glycemia; head-to-head data show greater average weight loss with tirzepatide.